Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Biosimilar pharmaceuticals

FDA approves first biosimilar for breast and stomach cancers

The US Food and Drug Administration has given the go-ahead for Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab), for the treatment of patients with breast or metastatic stomach cancer.

The first biosimilar for the treatment of breast and stomach cancers has been approved by the US Food and Drug Administration (FDA).

The FDA has authorised Ogivri (trastuzumab-dkst) as a biosimilar to Herceptin (trastuzumab) for the treatment of patients with breast or metastatic stomach cancer (gastric or gastroesophageal junction adenocarcinoma) whose tumours over-express the HER2 gene (HER2+).

Ogivri is the first biosimilar approved in the US for the treatment of breast cancer or stomach cancer, and the second biosimilar approved in the US for the treatment of cancer, the agency said.

FDA commissioner Scott Gottlieb said: “The FDA continues to grow the number of biosimilar approvals, helping to promote competition that can lower healthcare costs. This is especially important when it comes to diseases like cancer that have a high cost burden for patients.”

“We’re committed to taking new policy steps to advance our biosimilar pathway and promote more competition for biological drugs,” he added.

The FDA said Ogivri has been approved as a biosimilar, not as an interchangeable product, and it highlighted the fact that, like Herceptin, the labelling for Ogivri contains a boxed warning to alert healthcare professionals and patients about increased risks of heart disease, infusions reactions, lung damage and harm to a developing foetus.

Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2017.20204067

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Supplementary images

  • breast mammography

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.